(IN BRIEF) ZEISS Ventures has participated in the latest funding round of Maculaser, a Finnish medtech company developing a patented, non-damaging, temperature-controlled retinal laser therapy. The round, co-led by ZEISS Ventures and M2care, will help Maculaser begin clinical development of … Read the full press release →
Posted in Business, Financial, Finland, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Science, Technology
Tagged Aalto University, age-related macular degeneration, AMD, cellular defence mechanisms, clinical development, data-driven laser therapy, diabetic maculopathy, Early Intervention, Finland, Finnish medtech, Germany, healthtech, Jani Tirronen, late-stage AMD, M2care, Maculaser, Maculaser Advances Temperature-Controlled Retinal Laser Technology With Support From ZEISS Ventures and M2care, medical technology, non-damaging treatment, OBERKOCHEN, ophthalmic innovation, ophthalmologists, outpatient procedure, personalised retinal treatment, proactive vision preservation, Prof Dr Boris Hofmann, real-time temperature control, repeatable treatment, retinal diseases, retinal laser therapy, retinal tissue, severe vision loss, temperature-controlled laser therapy, vision loss prevention, ZEISS, ZEISS Backs Finnish Medtech Maculaser in Development of Data-Driven Laser Therapy for Retinal Diseases, ZEISS Group, ZEISS Ventures, ZEISS Ventures Investment Supports Maculaser’s Effort to Shift Retinal Care Toward Earlier Vision Preservation, ZEISS Ventures Invests in Maculaser to Advance Non-Damaging Retinal Laser Therapy for Earlier Eye Disease Treatment, ZEISS Ventures Invests in Maculaser to Support Development of Temperature-Controlled Retinal Laser Therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
